Etoposide Capsule
NDC Package 83270-451-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Etoposide capsules is etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). This formulation utilizes a capsule delivery system. Marketed by Onesource Specialty Pharma Limited, this product is identified by NDC 83270-451 and is authorized under FDA application NDA019557.

Identification & Billing

NDC Package Code
83270-451-05
Package Description
20 CAPSULE in 1 CARTON
Product Code
83270-451
11-Digit Billing Format
83270045105
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Etoposide
Non-Proprietary Name
Etoposide
Substance Name
Etoposide
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ETOPOSIDE 50 mg/1
Pharmacologic Class
Usage Information
Etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). Etoposide works by slowing the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Onesource Specialty Pharma Limited
Product Type
Human Prescription Drug
FDA Application #
NDA019557
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-29-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83270-451-05 identifies a specific commercial package of 20 capsule in 1 carton of Etoposide, a human prescription drug labeled by Onesource Specialty Pharma Limited. This capsule is formulated for oral use and contains etoposide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Onesource Specialty Pharma Limited on May 29, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). Etoposide works by slowing the growth of cancer cells.

How is this Onesource Specialty Pharma Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83270045105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83270-451-05
11-Digit CMS (5-4-2)
83270-0451-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.